

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 89559

**Title:** Revolutionizing gastric cancer treatment: The potential of immunotherapy

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03299464

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Associate Professor, Chief Technician

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Greece

**Manuscript submission date:** 2023-11-05

**Reviewer chosen by:** Jia-Ru Fan

**Reviewer accepted review:** 2023-11-20 00:20

**Reviewer performed review:** 2023-11-20 01:14

**Review time:** 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

The language of the manuscript is concise and accurate. This editorial summarizes the current frontier progress of immune checkpoint inhibitors, in-depth research and clinical trials in this field, as well as the efficacy and toxicity of various therapies. To meet the clinical demand for precision medicine, the new precise detection of biomarkers helps to promote personalized customization to use these therapies, which has great guiding significance for future clinical treatment and diagnosis. Limitations: If possible, supplement the current main clinical toxicity status of immunosuppressants, and accurate testing of molecular markers for immune checkpoint inhibitors.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 89559

**Title:** Revolutionizing gastric cancer treatment: The potential of immunotherapy

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 07225840

**Position:** Peer Reviewer

**Academic degree:** MSc

**Professional title:** Research Fellow

**Reviewer's Country/Territory:** India

**Author's Country/Territory:** Greece

**Manuscript submission date:** 2023-11-05

**Reviewer chosen by:** Jia-Ru Fan

**Reviewer accepted review:** 2023-11-19 04:44

**Reviewer performed review:** 2023-11-26 06:32

**Review time:** 7 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### SPECIFIC COMMENTS TO AUTHORS

The editorial appears to be comprehensive and well structured. It will be nice if the authors could reconsider some points- 1. Better and in-depth description is required for the tumor vaccines. Specially stressing upon variety and clinical implications of the vaccines. 2. It will be nice if there is a mention of various molecular and genetic biomarkers for gastric cancer, and their significance in designing of the specific immunotherapy.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 89559

**Title:** Revolutionizing gastric cancer treatment: The potential of immunotherapy

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 04056477

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Associate Professor, Deputy Director

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Greece

**Manuscript submission date:** 2023-11-05

**Reviewer chosen by:** Jia-Ru Fan

**Reviewer accepted review:** 2023-11-21 07:45

**Reviewer performed review:** 2023-12-01 02:27

**Review time:** 9 Days and 18 Hours

Scientific quality	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Very good <input type="radio"/> Grade C: Good <input type="radio"/> Grade D: Fair <input type="radio"/> Grade E: Do not publish
Novelty of this manuscript	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Good <input type="radio"/> Grade C: Fair <input type="radio"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Good <input type="radio"/> Grade C: Fair <input type="radio"/> Grade D: No creativity or innovation

<b>Scientific significance of the conclusion in this manuscript</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

The abstract and content provide a comprehensive overview of gastric cancer, its current treatments, and the promising advancements in immunotherapy. Here's an English commentary: Abstract: The abstract effectively encapsulates the global prevalence of gastric cancer, highlighting its prominence in Eastern Europe and Asia. The enumeration of risk factors, diagnostic challenges, and grim prognosis sets the stage for the discussion on immunotherapy. The reference to the specific article by Li et al. adds credibility and situates the editorial within the context of recent research. Introduction: The introduction adeptly introduces the severity of gastric cancer and its diagnostic challenges. The mention of surgical intervention and its limited success sets the tone for the subsequent exploration of immunotherapy. The reference to NCCN guidelines provides a practical context for the current standard of care. Main Text: The main text is thorough and well-organized. The discussion on immune checkpoint inhibitors (ICIs) is particularly detailed, offering insights into their mechanisms and conflicting findings regarding prognostic implications. The meta-analysis by Liu et al. adds valuable evidence to support the potential superiority of ICIs over traditional chemotherapy. The inclusion of



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

specific regimens for different molecular subtypes of gastric cancer enhances the practical applicability of the information. The exploration of tumor vaccines, focusing on dendritic cells and mRNA vaccines, is insightful. The acknowledgment of challenges related to immunogenicity and immune evasion in gastric cancer adds nuance to the discussion. The bibliometric analysis by Li et al. contributes a quantitative dimension to the evaluation of tumor vaccines. The section on Adoptive Immunotherapy is comprehensive, covering TIL therapy, engineered TCR therapy, CAR-T therapy, NK cell therapy, and CIK cells. The emphasis on biomarkers and specific targets enriches the discussion. The mention of ongoing clinical trials and the potential of fourth-generation CAR-T therapy indicates the dynamic nature of research in this field. Conclusion: The conclusion effectively summarizes the advancements in immunotherapy, especially since the development of Immune Checkpoint Inhibitors. The mention of ongoing research and the integration of immunotherapy for precision medicine aligns with the evolving landscape of cancer treatment. Overall Impression: The editorial is well-researched, providing a balanced blend of statistical data, clinical evidence, and future prospects. The language is clear, and the structure facilitates a smooth flow of information. It successfully communicates the urgency of finding effective treatments for gastric cancer and the promising role of immunotherapy in this endeavor. This editorial can be accepted for publication.